JIMRO Co., Ltd.
Corporate brand
UnclaimedJapanese medical device company in the Otsuka Group, known for the Adacolumn granulocyte apheresis device and other therapeutic and diagnostic products.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
JIMRO Co., Ltd. is a Japanese medical device manufacturer headquartered in Takasaki, Gunma Prefecture, and a member of the Otsuka Group. The company was established in November 1977 as Nippon Kotai Kenkyusho Co., Ltd. (Japan Antibody Research Institute), one of the satellite research laboratories of the Otsuka Group, initially focused on immunology research and the manufacture and sale of research reagents. It changed its name to JIMRO Co., Ltd. in October 2005. Its parent company is Otsuka Medical Devices Co., Ltd. JIMRO develops, manufactures, sells, leases, imports and exports medical devices, and conducts research and development. Its best-known product is Adacolumn, a granulocyte apheresis device used in the treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) and other conditions. Adacolumn received manufacturing approval in Japan for ulcerative colitis in 1999 and insurance coverage in 2000, followed by additional indications for Crohn's disease (2008/2009), pustular psoriasis (2012), psoriatic arthritis (2019), ulcerative colitis remission maintenance (2021/2022), and sepsis (2024/2025). The company also markets the Tron FX thrombectomy device, the Presgo detachable coil system, and the AJIRO colonic stent, and previously produced the JIMRO II RLP-cholesterol in vitro diagnostic. JIMRO positions itself around the corporate philosophy of creating innovative products and delivering professional services for better health worldwide, with a strong emphasis on employee health and CSR activities. It operates from its Takasaki head office with additional offices in Tokyo and Osaka, and reported 137 employees as of March 1, 2026, with capital of 100 million yen. The company is led by President and Representative Director Tomoya Adachi.
History
JIMRO Co., Ltd. traces its origins to November 1977, when it was founded as Nippon Kotai Kenkyusho Co., Ltd. (Japan Antibody Research Institute), one of the satellite research laboratories of the Otsuka Group. Its initial activities centered on immunology research and the manufacture and sale of research reagents. A research building was completed in July 1991. In the 1990s the company moved toward diagnostic and therapeutic products. In September 1995 it obtained manufacturing approval in Japan for the in vitro diagnostic RLP-cholesterol 'JIMRO II'. In July 1999 it opened a Tokyo office, and in September 1999 it received US FDA 510(K) clearance for JIMRO II for type III hyperlipidemia, followed in July 2000 by FDA 510(K) clearance for use as a cardiovascular risk indicator. In October 1999 Adacolumn received manufacturing approval in Japan for the treatment of ulcerative colitis, and in April 2000 it obtained insurance coverage in Japan. A new Adacolumn factory was established in April 2001, and an Osaka office opened in July 2001. A Tokyo office annex followed in April 2003, and in March 2004 the company obtained import and sales approval in Japan for a PTCA balloon catheter. In October 2005 the company changed its name from Nippon Kotai Kenkyusho Co., Ltd. to JIMRO Co., Ltd. It continued to expand the indications for Adacolumn: additional efficacy for Crohn's disease was obtained in September 2008 with insurance coverage in January 2009; for pustular psoriasis in June 2012 with insurance coverage in October 2012; for psoriatic arthritis in June 2019 with insurance coverage in November 2019; for ulcerative colitis remission maintenance in July 2021 with insurance coverage in January 2022; and for sepsis in November 2024 with insurance coverage from August 2025. In March 2016 the Presgo detachable coil system received manufacturing and marketing approval in Japan. In February 2017 JIMRO acquired all shares of Biomedical Solutions Co., Ltd. In December 2018 the Tron FX thrombectomy device received manufacturing and marketing approval in Japan, and in December 2019 that approval was transferred to Biomedical Solutions. In March 2023 the AJIRO colonic stent received manufacturing and marketing approval in Japan, with insurance coverage in May 2023. Today JIMRO operates as a medical device company within the Otsuka Group under parent Otsuka Medical Devices Co., Ltd., headquartered in Takasaki, Gunma, with offices in Tokyo and Osaka. As of March 1, 2026 it reported 137 employees and capital of 100 million yen, and is led by President and Representative Director Tomoya Adachi.
Founded as Nippon Kotai Kenkyusho Co., Ltd. (Japan Antibody Research Institute), a satellite research laboratory of the Otsuka Group
Research building completed
RLP-cholesterol 'JIMRO II' in vitro diagnostic obtained manufacturing approval in Japan
Tokyo office opened
JIMRO II received US FDA 510(K) clearance for type III hyperlipidemia
Adacolumn received manufacturing approval in Japan for ulcerative colitis treatment
Adacolumn obtained insurance coverage in Japan for ulcerative colitis
JIMRO II received US FDA 510(K) clearance as a cardiovascular risk indicator
New Adacolumn factory established
Osaka office opened
Products and positioning
Specialized medical device maker within the Otsuka Group focused on apheresis therapy, cerebrovascular treatment devices, and gastrointestinal devices, guided by a philosophy of contributing to health worldwide.
Adacolumn
Granulocyte apheresis device for inflammatory bowel disease and other conditions
Tron FX
Thrombectomy device
Presgo
Detachable coil system
AJIRO
Colonic stent
JIMRO II
RLP-cholesterol in vitro diagnostic
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/jimro-co-ltd-japan · Editorial policy · How profiles are compiled